Eli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales
Eli Lilly reported Q3 2026 revenue of $24.4B, beating estimates by 7.9%, and raised full-year revenue guidance to $91.5B. Adjusted EPS was $7.48, a 13.2% beat, but full-year EPS guidance was lowered to $35.50 due to non-recurring charges.
How this was made
The 30-second read
Why it matters
Traders can update positioning immediately because the article provides both the quarter’s beat metrics and the revised full-year guidance midpoints, including the stated reason for the EPS change.
Market read
A guidance raise on revenue alongside a modest adjusted EPS midpoint reduction creates a tradable mix for earnings-multiple and margin-sensitive positioning.
What to watch
Operating margin fell to 35.3% from 41.8% a year ago, which could limit upside if investors focus on profitability trajectory rather than revenue growth.
Background
The piece summarizes Lilly’s Q3 2026 performance versus consensus and details updated full-year revenue and adjusted EPS guidance.
Ticker impact
Eli Lilly reported Q3 2026 revenue and EPS beats and lifted full-year revenue guidance to $91.5B midpoint while adjusting EPS guidance lower.
Likely upward bias as the market reprices stronger full-year revenue, partially offset by concern over the reduced adjusted EPS midpoint.
The article contains fresh, company-specific guidance changes: revenue guidance raised and adjusted EPS guidance lowered, with explicit midpoint figures and stated drivers (non-recurring acquired IPR&D charges).
Market effects
Large-cap pharma peers may see read-through on demand durability and margin normalization assumptions, especially given the operating margin decline.
US large-cap healthcare sentiment may improve on the guidance raise, supporting sector flows.
Global pharma investors may recalibrate 2026 growth expectations for the sector based on Lilly’s raised revenue outlook.
Counterpoint
The EPS guidance cut, driven by acquired IPR&D charges, may signal underlying cost or deal-related drag that could persist beyond non-recurring items.
Key entities
- companyEli Lilly
US-listed pharma company reporting Q3 2026 results and updated full-year revenue and adjusted EPS guidance.
